Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
about
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesInhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerThe Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Targeting the androgen receptor in prostate cancer.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.Proinflammatory cytokine interleukin-6 in prostate carcinogenesisInvestigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Role of STAT3 pathway in genitourinary tumors.Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.Role of miRNA let-7 and its major targets in prostate cancer.Stromal TGF-β signaling induces AR activation in prostate cancer.Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain
P2860
Q26751237-447258C8-795C-49B6-9CF4-148F54BFF684Q26796704-6B568306-F65B-40F7-8AF0-691C442F16F9Q33780482-B041BC38-D45D-402F-B389-7AB181808A7FQ34461177-E9D2B621-86F7-49C9-868F-2C24B0ADE9AEQ35150756-9FA71F73-5CE3-4667-A572-C247937064E8Q38203779-72624183-2F5D-42C5-ABED-9DAF7711F6FEQ38217060-32A34F19-96A0-423B-9F66-1F2B6040E658Q38259197-A2CBE51B-7FC4-44A8-ADC1-1203B31EF400Q38265575-8E00392B-D3EE-4F91-9B78-74AD8784DCF4Q38369000-DA92346E-D9F1-4248-A28C-391FD4D63E39Q38643148-504CCBDB-C1D8-464F-8BF2-414DBA4967B3Q38735379-B3F7E19B-FC74-433D-BE7E-F115FF3B274BQ38754074-3A81CBC8-EFFF-4ABA-874A-1A0FBAABC396Q38776978-CEDE8AE7-F4CA-40CD-AC74-849E24FF7680Q38875469-9097E295-88FC-44A6-BE9B-82F3EF486ED5Q39021945-8B8FD8B3-0FB5-4C90-8B26-370DCC6D7216Q41167484-8F6CFCBF-98D1-451E-BC1D-1A5BF7F668DAQ41561381-E4A55EBC-EBB1-430A-8978-218B2BD4BAA2Q41890041-C0226615-6722-447B-8933-9173975AF15CQ43084872-6AB69156-1B86-4718-A06E-184CF16588FFQ46095028-2B91DC69-D489-441A-9BC9-B8E00E1645FFQ47109527-06F627A0-035E-472D-9DDA-EACCB4274800Q49483643-79DC3879-63CB-4269-BA6B-B38C3D80CAA5Q53735518-53F5AC6A-BF7D-493A-8B07-11C18FBFF4B3Q58611891-DEAC611E-DD54-4FDF-AA48-9D80FE47C7BE
P2860
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Inhibition of constitutively a ...... rivative prostate cancer cells
@ast
Inhibition of constitutively a ...... rivative prostate cancer cells
@en
Inhibition of constitutively a ...... rivative prostate cancer cells
@nl
type
label
Inhibition of constitutively a ...... rivative prostate cancer cells
@ast
Inhibition of constitutively a ...... rivative prostate cancer cells
@en
Inhibition of constitutively a ...... rivative prostate cancer cells
@nl
prefLabel
Inhibition of constitutively a ...... rivative prostate cancer cells
@ast
Inhibition of constitutively a ...... rivative prostate cancer cells
@en
Inhibition of constitutively a ...... rivative prostate cancer cells
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of constitutively a ...... rivative prostate cancer cells
@en
P2093
Allen C Gao
Chengfei Liu
Christopher P Evans
Yuanyuan Cui
P2860
P304
P356
10.1002/PROS.22741
P577
2013-10-16T00:00:00Z